$XLO News

Xilio Therapeutics Q1 EPS $(0.58) Beats $(0.66) Estimate, Sales $12.648M Beat $8.520M Estimate

Xilio's XTX601 Shows Tumor-Selective Activation And Strong Preclinical Anti-Tumor Activity With Favorable Safety Profile At AACR 2026

Xilio Therapeutics Q4 EPS $0.81 Beats $(0.12) Estimate, Sales $13.686M Beat $7.960M Estimate

Xilio Therapeutics Announces XTX501 Shows Robust Monotherapy Activity; Plans IND Submission In Middle Of 2026; Intends To Start Phase 1 Study Of XTX501 In H2 This Year

Xilio Therapeutics shares are trading higher after the company announced an upcoming poster presentation entitled "Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager" at the American Association for Cancer Research annual meeting from April 17-22, 2026.

Xilio Therapeutics shares are trading higher after the company announced an upcoming poster presentation entitled "Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager" at the American Association for Cancer Research annual meeting from April 17-22, 2026.

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Xilio Therapeutics Announces 1-For-14 Reverse Stock Split, Effective March 13

Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reported Earlier, Xilio Therapeutics Prices Underwritten Offering Of 74,780,300 Pre-Funded Warrants At $0.5349 Per Warrant For $40M Gross Proceeds

Xilio Therapeutics Announces Pricing of Underwritten Offering

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results

Xilio Therapeutics Q3 EPS $(0.11) Misses $(0.03) Estimate, Sales $19.066M Beat $18.635M Estimate

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript

Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting

Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting